Lv12
40 积分 2025-12-24 加入
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial
16小时前
已完结
Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer
16小时前
已完结
Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study
16小时前
已完结
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study
16小时前
已完结
Patterns of Disease Progression after Carboplatin/Etoposide + Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
16小时前
已完结
MA11.04 Safety of Lurbinectedin + Atezolizumab as 1L Maintenance Treatment in ES-SCLC: Results From the Phase 3 IMforte Study
16小时前
求助中
Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis
26天前
已完结
331P: A single-arm, open-label, prospective, single-center clinical study on the treatment of patinum-resistant relapse small cell lung cancer with nab-paclitaxel combined with apatinib
4个月前
已关闭
P1.15-009 Safety and Efficacy of Nab-Paclitaxel Monotherapy as 2nd or Later Line Setting in Pts with Extensive SCLC, a Phase II Single Arm Study (NCT02262897)
4个月前
已完结
Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
4个月前
已完结
JDMAN: Joint Discriminative and Mutual Adaptation Networks for Cross-Domain Facial Expression Recognition
皖公网安备34019202002308
